To identify hub genes specific to the immune-active phase of chronic hepatitis B (CHB) and explore their potential roles in immune modulation, which is crucial for developing effective therapies.
Key Findings:
Identified 36 differentially expressed genes (DEGs) unique to the immune-active phase, highlighting their potential role in immune response.
Discovered four hub genes: CCR5, IL10RA, KCNA3, and SLC24A4, with SLC24A4 being particularly significant.
SLC24A4 expression was significantly elevated in the immune-active phase and associated with pro-inflammatory macrophage infiltration, indicating its role in immune modulation.
In silico knockout of SLC24A4 indicated its role as a negative regulator of monocyte activation, suggesting a compensatory mechanism during inflammation.
Interpretation:
SLC24A4 may serve as a critical regulator of immune response during the immune-active phase of CHB, suggesting its potential as a therapeutic target for immune modulation, which could enhance treatment outcomes.
Limitations:
Study primarily focused on peripheral monocytes; other immune cell types were not extensively analyzed, which may limit the understanding of the overall immune response.
Findings based on bioinformatics and may require further clinical validation to confirm their applicability.
Conclusion:
The study highlights the transcriptional characteristics of the CHB immune-active phase and positions SLC24A4 as a potential target for therapeutic intervention in immune modulation, paving the way for future research and treatment strategies.
